Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Update

Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 8,520,000 shares, a decrease of 18.2% from the November 15th total of 10,410,000 shares. Based on an average daily volume of 655,500 shares, the days-to-cover ratio is presently 13.0 days. Currently, 11.9% of the company’s shares are sold short.

Organogenesis Trading Down 3.7 %

Shares of ORGO traded down $0.13 during trading hours on Friday, hitting $3.40. The stock had a trading volume of 533,181 shares, compared to its average volume of 843,073. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a market cap of $450.77 million, a P/E ratio of -56.67 and a beta of 1.73. The company’s fifty day simple moving average is $3.42 and its 200 day simple moving average is $2.98. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.70.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same period in the prior year, the firm earned $0.02 EPS. Equities research analysts forecast that Organogenesis will post -0.07 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Gary S. Gillheeney sold 18,416 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $3.65, for a total value of $67,218.40. Following the transaction, the chief executive officer now directly owns 3,400,778 shares of the company’s stock, valued at approximately $12,412,839.70. This trade represents a 0.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 216,916 shares of company stock valued at $784,832 in the last quarter. 36.90% of the stock is currently owned by company insiders.

Institutional Trading of Organogenesis

Several large investors have recently added to or reduced their stakes in ORGO. Captrust Financial Advisors acquired a new stake in Organogenesis in the 3rd quarter valued at $36,000. Pallas Capital Advisors LLC acquired a new stake in shares of Organogenesis during the second quarter valued at about $38,000. Delap Wealth Advisory LLC acquired a new stake in shares of Organogenesis during the second quarter valued at about $40,000. Intech Investment Management LLC acquired a new stake in shares of Organogenesis during the third quarter valued at about $43,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after acquiring an additional 15,369 shares in the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.